SHP2/CDK4-IN-1 manufacturers
- SHP2/CDK4-IN-1
-
- $1520.00
-
2026-07-27
- CAS:2924036-87-1
- Purity:
- Supply Ability: 10g
|
| | SHP2/CDK4-IN-1 Basic information |
| Product Name: | SHP2/CDK4-IN-1 | | Synonyms: | SHP2/CDK4-IN-1;2-Oxa-8-azaspiro[4.5]decan-4-amine, 8-[5-[[3-chloro-2-[[5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinyl]amino]-4-pyridinyl]thio]-2-pyrazinyl]-3-methyl-, (3S,4S)- | | CAS: | 2924036-87-1 | | MF: | C33H35ClF2N10OS | | MW: | 693.21 | | EINECS: | | | Product Categories: | | | Mol File: | 2924036-87-1.mol |  |
| | SHP2/CDK4-IN-1 Chemical Properties |
| Boiling point | 870.103±75.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.533±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 9.278±0.40(predicted) |
| | SHP2/CDK4-IN-1 Usage And Synthesis |
| Uses | SHP2/CDK4-IN-1 (compound 10) is an orally active and potent SHP2 and CDK4 dual inhibitor, with IC50 values of 4.3 and 18.2 nM, respectively. SHP2/CDK4-IN-1 effectively induces G0/G1 arrest to prevent the proliferation of TNBC cell lines. SHP2/CDK4-IN-1 shows significant antitumor efficacy in the EMT6 syngeneic mouse model. SHP2/CDK4-IN-1 can be used for triple-negative breast cancer (TNBC) research[1]. | | IC 50 | CDK4: 18.2 ± 1.3 nM (IC50) | | References | [1] Chen X, et al. Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2022 May 12;65(9):6729-6747. DOI:10.1021/acs.jmedchem.2c00063 |
| | SHP2/CDK4-IN-1 Preparation Products And Raw materials |
|